Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep;23(9):2978-85.
doi: 10.1096/fj.09-129874. Epub 2009 Apr 17.

Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice

Hui-Fang Zhou  1 , Happy W Chan, Samuel A Wickline, Gregory M Lanza, Christine T N Pham
Affiliations

Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice

Hui-Fang Zhou et al. FASEB J. 2009 Sep.

Abstract

The purpose of this study was to assess whether an alternative treatment approach that targets angiogenesis, delivered through ligand-targeted nanotherapy, would ameliorate inflammatory arthritis. Arthritis was induced using the K/BxN mouse model of inflammatory arthritis. After arthritis was clearly established, mice received three consecutive daily doses of alpha(v)beta(3)-targeted fumagillin nanoparticles. Control groups received no treatment or alpha(v)beta(3)-targeted nanoparticles without drugs. Disease score and paw thickness were measured daily. Mice that received alpha(v)beta(3)-targeted fumagillin nanoparticles showed a significantly lower disease activity score (mean score of 1.4+/-0.4; P<0.001) and change in ankle thickness (mean increase of 0.17+/-0.05 mm; P<0.001) 7 d after arthritis induction, whereas the group that received alpha(v)beta(3)-targeted nanoparticles without drugs exhibited a mean arthritic score of 9.0 +/- 0.3 and mean change in ankle thickness of 1.01 +/- 0.09 mm. Meanwhile, the group that received no treatment showed a mean arthritic score of 9.8 +/- 0.5 and mean change in ankle thickness of 1.05 +/- 0.10 mm. Synovial tissues from animals treated with targeted fumagillin nanoparticles also showed significant decrease in inflammation and angiogenesis and preserved proteoglycan integrity. Ligand-targeted nanotherapy to deliver antiangiogenic agents may represent an effective way to treat inflammatory arthritis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Rhodamine-conjugated αvβ3-targeted nanoparticles (nps) accumulate specifically in arthritic paws. Arthritis was induced by intraperitoneal injection of K/BxN serum as described in Materials and Methods. On d 7 after serum transfer, at the peak of disease, arthritic mice were injected intravenously with the indicated rhodamine-conjugated nps. Normal mice served as controls. Concomitant injection of FITC-conjugated lectin outlined blood vessels (v) in green, while nps fluoresced in red. Arrowheads indicate colocalization (yellow) of nps to areas of blood vessels. Scale bar = 0.1 mm.
Figure 2.
Figure 2.
Targeted nanotherapy suppresses K/ BxN serum-induced arthritis. Arthritis was induced by intraperitoneal injection of K/BxN serum, and arthritis development (A) and changes in ankle thickness (B) were monitored daily by two independent observers. Starting on d 2 after serum transfer, when arthritis was clearly established in all animals, mice were given 3 daily intravenous doses of either αvβ3-targeted nps without drugs or αvβ3-targeted nps with 1.5 mol% fumagillin. Another control group received no treatment. Values are means ± se; n = 6–7 mice/group. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 3.
Figure 3.
Targeted nanotherapy reduces inflammatory cell influx, proteoglycan depletion, and angiogenesis. On d 7 after K/BxN serum transfer, groups of mice that received αvβ3-targeted nps without drugs or αvβ3-targeted nps with fumagillin were sacrificed, their paws were harvested, and sections were stained with H&E (A, B, E, F) to assess degree of inflammation and inflammatory cell influx, with toluidine blue (C, G) to assess the proteoglycan content in cartilage, or with an antibody to vWF to visualize blood vessels (arrows, D, H). Insets from A and E are shown at higher magnification in B and F, respectively. Scale bars = 0.5 mm (A, E); 0.05 mm (B, F); 0.1 mm (C, G); 0.02 mm (E, H). Micrographs represent 10 paws/group. Number of leukocytes (I) per HPF, degree of proteoglycan depletion by toluidine blue staining (J), and number of vWf+ blood vessels (K) per HPF were assessed in a masked fashion. Values are means ± se; 5 random fields/paw, 10 paws/group. *P < 0.0001. B, bone; JS, joint space; S, subsynovial tissue.
Figure 4.
Figure 4.
αvβ3-Targeted nanoparticles accumulate in the reticuloendothelial system. A) Cryosections from different organs were examined for nanoparticle accumulation (red). Blood vessels were visualized with FITC-lectin (green). On d 5 after the initiation of nanoparticle injection, blood samples were drawn, and liver enzymes, including serum concentrations of aspartate aminotransferase (AST; B), alanine aminotransferase (ALT; C), and alkaline phosphatase (AP; D) were assessed. Increase in liver enzymes was transient, with levels falling toward normal on d 11 after initiation of nanotherapy (E). Values are means ± se; 3–4 animals/group. *P < 0.05; **P < 0.01.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gartlehner G, Hansen R A, Jonas B L, Thieda P, Lohr K N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006;33:2398–2408. - PubMed
    1. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg A, Kapelle A, Listing J. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54:3399–3407. - PubMed
    1. Siddiqui M A. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Curr Opin Rheumatol. 2007;19:308–313s. - PubMed
    1. Buch M H, Bingham S J, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology. 2007;46:1153–1156. - PubMed
    1. Tarner I H, Muller-Ladner U, Gay S. Emerging targets of biologic therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2007;3:336–345. - PubMed

Publication types

MeSH terms

LinkOut - more resources